About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

PPAR-gamma: a Novel Therapeutic Target for Asthma? | Clinical Trials | Clareo Health

Back to clinical trial search

TERMINATEDPhase 4NCT01134835

PPAR-gamma: a Novel Therapeutic Target for Asthma?

To test the hypothesis that stimulation of PPAR-γ receptors has a therapeutic role in the treatment of asthma.

Lead sponsor: University of Nottingham•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Nottingham

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Age 18-75 of either sex with a clinical diagnosis of asthma,
•FEV1 ≥ 60% predicted and an increase in FEV1 of greater than 12% following inhaled salbutamol 400μg or Peak Expiratory Flow (PEF) variability \>12% during run-in.
•Allowed medication: 0-800μg inhaled beclomethasone diproprionate or equivalent and as required short acting beta agonist.

Exclusion Criteria

•Current smoking,
•\> 10 pack years smoking history,
•Treatment with leukotriene antagonists,
•Liver or cardiovascular disease,
•Oral steroid treatment or exacerbation within 6 weeks,
•Females who are pregnant, lactating or not using adequate contraception,
•Any contra-indication to pioglitazone (hypersensitivity to pioglitazone, cardiac failure, history of cardiac failure, hepatic impairment, diabetic ketoacidosis),
•Oral or insulin treatment for diabetes,
•Treatment with gemfibrozil or rifampicin.

Related studies

RECRUITINGPhase 2

Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma

NCT07301736 · Asthma

Remote Anxiety Management for ICS-resistant Asthma Study

NCT06732141 · Asthma

RECRUITINGPhase 2

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263 · Asthma

Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis

NCT07245576 · Asthma, COPD

Obstructive Sleep Apnoea and Difficult Asthma (OSADA)

NCT07160868 · Asthma (Diagnosis), OSA - Obstructive Sleep Apnea, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 3, 2015Terms

Trial snapshot

StatusTERMINATED

PhasePHASE4

Enrollment68

Start dateJun 2010

Last updatedDec 3, 2015

Condition

Locations shown

Nottingham University Hospitals NHS Trust

Nottingham

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 3, 2015Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions